Detection of intracerebral targets with imaging probes is challenging due to the non-permissive nature of blood-brain barrier (BBB). Camelid single-domain antibody-fragments (VHH) are small and stable antibodies able to potentially cross the BBB. Here, we selected VHH specifically targeting amyloid-beta deposits, one of the main lesions of Alzheimer’s disease and labeled them with the contrastophore gadolinium. These innovative contrast agents allowed MRI detection of amyloid deposits in postmortem brain tissues of a mouse model of amyloidosis. The ability to produce VHH conjugates that cross the BBB opens the way for future development of tailored imaging probes targeting intracerebral antigens.